Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call April 1, 2026 8:00 AM EDT
Company Participants
Joanne Choi
Laurent Levy – Co-Founder, President of the Executive Board & CEO
Bart Van Rhijn – Chief Financial & Business Officer and Member of Executive Board
Conference Call Participants
Tara Bancroft – TD Cowen, Research Division
Clemence Thiers – Stifel, Nicolaus & Company, Incorporated, Research Division
Albert Agustinus – Leerink Partners LLC, Research Division
Swayampakula Ramakanth – H.C. Wainwright & Co, LLC, Research Division
Xiaochuan Dai – UBS Investment Bank, Research Division
Michael Schmidt – Guggenheim Securities, LLC, Research Division
Shan Hama – Jefferies LLC, Research Division
Clément Bassat – Portzamparc BNP Paribas Group, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Nanobiotix Full Year 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Joanne Choi, Head of Investor Relations, U.S. Please go ahead.
Joanne Choi
Thank you, Heidi. Good afternoon, and good morning, and welcome to the Nanobiotix conference call to discuss our full year 2025 financial and operational results. Joining me on the call today are Laurent Levy, Co-Founder and Chief Executive Officer; and Bart Van Rhijn, Chief Financial and Business Officer. Today’s call is being webcast and will be available on our website for replay. Before we begin, I would like to remind you that today’s discussion will include forward-looking statements within the meaning of applicable securities laws. These statements are based on our current expectations, assumptions and available information and are subject to significant risks and uncertainties that could cause actual results to differ materially.
Such risks include, among others, those related to the timing, progress and outcomes of our research and clinical development programs, regulatory developments and our financial and operational performance. We